Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
51 results about "Mevalonate pathway" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The mevalonate pathway, also known as the isoprenoid pathway or HMG-CoA reductase pathway is an essential metabolic pathway present in eukaryotes, archaea, and some bacteria. The pathway produces two five-carbon building blocks called isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are used to make isoprenoids, a diverse class of over 30,000 biomolecules such as cholesterol, vitamin K, coenzyme Q10, and all steroid hormones.
The invention belongs to the technical field of microorganisms and fermentationengineering, and particularly relates to yarrowia lipolytica engineeringbacteria for producing zeaxanthin as well as a construction method and application of the yarrowia lipolytica engineeringbacteria. Specifically, the yarrowia lipolytica is subjected to genetic engineering modification based on a genetic engineering technology, a zeaxanthin biosynthetic pathway is constructed by expressing beta-carotene hydroxylase in an original strain, and meanwhile, a zeaxanthin biosynthetic pathway is constructed through a multiple metabolic engineering modification strategy. The method comprises the steps of key enzyme PaCrtZ multi-copy integration, oxidation-reduction balance regulation and control, upstream mevalonic acid pathway enhancement through membrane-free organelles and the like, and the yield of zeaxanthin is further increased. Meanwhile, by optimizing the culture conditions and applying the optimal fermentation conditions to perform tank fermentation, the yarrowia lipolytica can continuously generate more zeaxanthin, so that the yarrowia lipolytica has excellent practical application value and application prospect.
The present invention provides a recombinant microorganism for simultaneously producing sesquiterpenes and primary metabolites, wherein the primary metabolites include at least one of pantothenic acid, squalene, fatty acids and vitamin B2; the strain contains the mevalonate pathway, the β-farnesene synthesis gene and genes related to the synthesis of primary metabolites; the genes related to the mevalonate pathway include ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1, IDI1 and ERG20 genes, and the copy numbers are ERG10:ERG13:tHMG1:ERG12:ERG8:MVD1:IDI1:ERG20 = 2:2:X:2:2:2:2:2, where X is an integer greater than or equal to 1; the β-farnesene synthesis gene includes bFS, and the sequence is as shown in SEQ ID NO.1. The present invention realizes high yield of primary metabolites while producing sesquiterpene compounds.
The invention belongs to the technical field of enzymeengineering, and discloses a high-activity isopentenyl phosphokinase mutant and application thereof. The high-activity isopentenyl phosphokinase mutant is AtIPKH274P, and the amino acid at the 274 site of wild type AtIPK is mutated from histidine H to proline P. The invention further discloses a preparation method of the high-activity isopentenyl phosphokinase mutant. According to the present invention, the AtIPKH274P, the SmDAGKS47A and the L124A can form the efficient isopentenol utilization pathway so as to effectively convert the prenol into the DMAPP; an engineering strain with improved isopentenyl modification capability can be constructed by utilizing the approach, and the strain has more advantages compared with a traditional engineering strain based on a mevalonic acid approach.
The invention discloses a multi-gene tandem recombinant strain as well as a construction method and application thereof. The invention also discloses a method for synthesizing lycopene based on an isopentenol utilization approach. The strain comprises a recombinant strain of seven key genes, namely mtipk, thim, ispA, idi, crtE, crttheB and crtI, for synthesizing lycopene in an IUP (Inhibitory Urinary Protein) way. According to the invention, the isopentenol is introduced into the escherichia coli in a way to synthesize the lycopene; according to the approach, only two-step phosphorylation reaction is used for replacing the original 2-C-methyl-D-erythritol-4-phosphoric acid approach and mevalonic acid approach which need more than seven steps to synthesize precusor substances pentadienyl pyrophosphoric acid and dimethyl allyl pyrophosphate ester of lycopene, so that the metabolic pathway is greatly shortened, and competition with central carbon metabolism in cells is avoided; the toxicity caused by accumulation of intermediate products in the metabolic process is reduced, and lycopene can be efficiently synthesized by using a cheap substrate.
The invention discloses yarrowia lipolytica genetically engineeredbacteria for producing linalool as well as a construction method and application of the yarrowia lipolytica genetically engineeredbacteria. According to the invention, an optimized linalool synthase gene AaLIS from kiwi fruit is assembled by using polypeptide interaction tags RIAD-RIDD and ERG20WW, the assembled gene is converted into a mevalonic acid pathway enhanced chassis strain Yl-19, the Yl19 is used as an original strain, and the linalool synthase is obtained by overexpressing a key rate-limiting enzyme in a metabolic pathway, knocking out a key enzyme in a side reaction pathway and a multi-copy strategy. And the metabolic flux in the biosynthetic pathway of the yarrowia lipolytica alcoholysis is improved. The shake flaskfermentation yield of the constructed engineering strain Li-6 can reach 41.8 mg / L, the shake flaskfermentation yield of Li-27 reaches up to 178.4 mg / L and can be further increased to 665.8 mg / L by optimizing fermentation conditions, and the method is suitable for large-scale industrial production of linalool.
The invention discloses yarrowia lipolytica genetically engineeredbacteria capable of producing decaisopentenol and application of the yarrowia lipolytica genetically engineeredbacteria, and belongs to the technical field of bioengineering. The yarrowia lipolytica genetically engineered bacterium is obtained by cloning a decene diphosphate synthase gene into yarrowia lipolytica, overexpressing related genes of an endogenous acetyl coenzyme A synthetic pathway and a mevalonic acid pathway of the yarrowia lipolytica, weakening a squalene synthetic pathway and knocking out endogenous ylCOQ1 enzyme. Experiments prove that the yarrowia lipolytica genetically engineered bacterium can significantly improve the yield of decyl isopentenol, and the product serves as an important precursor for chemical synthesis of coenzyme Q10, so that the engineered bacterium and the product thereof can be applied to biochemical synthesis of coenzyme Q10. The method is green and efficient, and has important industrial application value.